To include your compound in the COVID-19 Resource Center, submit it here.

Taiho's S-1 misses Phase III endpoint

Taiho said S-1 plus cisplatin missed the primary endpoint of superior overall survival

Read the full 136 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE